scholarly journals Contrast enhancement by lipid-based MRI contrast agents in mouse atherosclerotic plaques; a longitudinal study

2012 ◽  
Vol 8 (1) ◽  
pp. 63-71 ◽  
Author(s):  
Brigit den Adel ◽  
Linda M. van der Graaf ◽  
Ivo Que ◽  
Gustav J. Strijkers ◽  
Clemens W. Löwik ◽  
...  
Keyword(s):  
Longitudinal Study ◽  
Contrast Agents ◽  
Contrast Enhancement ◽  
Mri Contrast Agents ◽  
Atherosclerotic Plaques ◽  
Mri Contrast

A design strategy for small molecule-based targeted MRI contrast agents: their application for detection of atherosclerotic plaques

2014 ◽  
Vol 12 (43) ◽  
pp. 8611-8618 ◽  
Author(s):  
Shimpei Iwaki ◽  
Kazuya Hokamura ◽  
Mikako Ogawa ◽  
Yasuo Takehara ◽  
Yasuaki Muramatsu ◽  
...  
Keyword(s):  
Contrast Agents ◽  
Small Molecule ◽  
Design Strategy ◽  
Mri Contrast Agents ◽  
Atherosclerotic Plaques ◽  
Mri Contrast ◽  
Targeted Mri

Molecular Magnetic Resonance Imaging for the Detection of Vulnerable Plaques

2013 ◽  
Author(s):  
Brigit den Adel ◽  
Mat J. Daemen ◽  
Robert E. Poelmann ◽  
Louise van der Weerd
Keyword(s):  
Contrast Agents ◽  
Mri Contrast Agents ◽  
Atherosclerotic Plaques ◽  
Resonance Imaging ◽  
Plaque Vulnerability ◽  
Mri Contrast ◽  
Atherosclerosis Development ◽  
Targeted Mri ◽  
Molecular Resonance

Recent advances in molecular resonance imaging of atherosclerosis enable to visualize atherosclerotic plaques in vivo using molecular targeted contrast agents. This offers opportunities to study atherosclerosis development and plaque vulnerability noninvasively. In this review, we discuss MRI contrast agents targeted toward atherosclerotic plaques and illustrate how these new imaging platforms could assist in our understanding of atherogenesis and atheroprogression. In particular, we highlight the challenges and limitations of the different contrast agents and hurdles for clinical application. We describe the most promising existing compounds to detect atherosclerosis and plaque vulnerability. Of particular interest are the fibrin-targeted compounds that detect thrombi and, furthermore, the contrast agents targeted to integrins that allow to visualize plaque neovascularization. Moreover, vascular cell adhesion molecule 1–targeted iron oxides seem promising for early detection of atherosclerosis. These targeted MRI contrast agents, however promising and well characterized in (pre)clinical models, lack specificity for plaque vulnerability.

In Vivo Evaluation of a PAMAM-Cystamine-(Gd-DO3A) Conjugate as a Biodegradable Macromolecular MRI Contrast Agent

2007 ◽  
Vol 232 (8) ◽  
pp. 1081-1089 ◽  
Author(s):  
Rongzuo Xu ◽  
Yanli Wang ◽  
Xuli Wang ◽  
Eun-Kee Jeong ◽  
Dennis L. Parker ◽  
...  
Keyword(s):  
Contrast Agent ◽  
Contrast Agents ◽  
Contrast Enhancement ◽  
Blood Pool ◽  
Pamam Dendrimers ◽  
Mri Contrast Agents ◽  
The Body ◽  
Mri Contrast Agent ◽  
High Toxicity ◽  
Mri Contrast

Macromolecular Gd(III) chelates are superior magnetic resonance imaging (MRI) contrast agents for blood pool and tumor imaging. However, their clinical development is limited by the safety concerns related to the slow excretion and long-term gadolinium tissue accumulation. A generation 6 PAMAM Gd(III) chelate conjugate with a cleavable disulfide spacer, PAMAM-G6-cystamine-(Gd-DO3A), was prepared as a biodegradable macromolecular MRI contrast agent with rapid excretion from the body. T1 and T2 relaxivities of the contrast agent were 11.6 and 13.3 m M−1sec−1 at 3T, respectively. Blood pool and tumor contrast enhancement of the agent were evaluated in female nude mice bearing MDA-MB-231 human breast carcinoma xenografts with a nondegradable conjugate PAMAM-G6-(Gd-DO3A) as a control. PAMAM-G6-cystamine-(Gd-DO3A) resulted in significant contrast enhancement in the blood for about 5 mins, and Gd-DO3A was released from the conjugate and rapidly excreted via renal filtration after the disulfide spacer was cleaved. The nondegradable control had much longer blood circulation and excreted more slowly from the body. PAMAM-G6-cystamine-(Gd-DO3A) also resulted in more prominent tumor contrast enhancement than the control. However, PAMAM-G6-cystamine-(Gd-DO3A) demonstrated high toxicity due to the intrinsic toxicity of PAMAM dendrimers. In conclusion, although PAMAM-G6-cystamine-(Gd-DO3A) showed some advantages compared with the nondegradable control, PAMAM dendrimers are not suitable carriers for biodegradable macromolecular MRI contrast agents, due to their high toxicity.

scholarly journals Contrast enhancement by differently sized paramagnetic MRI contrast agents in mice with two phenotypes of atherosclerotic plaque

2010 ◽  
Vol 6 (1) ◽  
pp. 35-45 ◽  
Author(s):  
Glenda S. van Bochove ◽  
Leonie E.M. Paulis ◽  
Dolf Segers ◽  
Willem J.M. Mulder ◽  
Rob Krams ◽  
...  
Keyword(s):  
Contrast Agents ◽  
Contrast Enhancement ◽  
Atherosclerotic Plaque ◽  
Mri Contrast Agents ◽  
Mri Contrast

Cubosomes as Carriers for MRI Contrast Agents

2017 ◽  
Vol 24 (5) ◽  
pp. 470-482 ◽  
Author(s):  
Nicolas Alcaraz ◽  
Ben J. Boyd
Keyword(s):  
Contrast Agents ◽  
Mri Contrast Agents ◽  
Mri Contrast

Biocompatible dextran-coated gadolinium-doped cerium oxide nanoparticles as MRI contrast agents with high T1 relaxivity and selective cytotoxicity to cancer cells

2021 ◽  
Author(s):  
Anton Popov ◽  
Maxim Artemovich Abakumov ◽  
Irina Savintseva ◽  
Artem Ermakov ◽  
Nelly Popova ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Contrast Agents ◽  
Mri Contrast Agents ◽  
Cerium Oxide Nanoparticles ◽  
Oxide Nanoparticles ◽  
Resonance Imaging ◽  
Mri Contrast ◽  
Selective Cytotoxicity ◽  
Magnetic Resonance Imaging Mri

Gd-based complexes are widely used as magnetic resonance imaging (MRI) contrast agents. The safety of previously approved contrast agents is questionable and is being re-assessed. The main causes of concern...

scholarly journals Correction to: Magnetic Nanoparticles as MRI Contrast Agents

2021 ◽  
Vol 379 (4) ◽  
Author(s):  
Ashish Avasthi ◽  
Carlos Caro ◽  
Esther Pozo-Torres ◽  
Manuel Pernia Leal ◽  
María Luisa García-Martín
Keyword(s):  
Magnetic Nanoparticles ◽  
Contrast Agents ◽  
Mri Contrast Agents ◽  
Mri Contrast

A correction to this paper has been published: https://doi.org/10.1007/s41061-021-00340-y

Sign in / Sign up

Export Citation Format

Share Document